Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma

Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL). The tisagenlecleucel chimeric antigen receptor (CAR) contains a murine single-chain varia...

Descripción completa

Detalles Bibliográficos
Autores principales: Thudium Mueller, Karen, Grupp, Stephan A., Maude, Shannon L., Levine, John E., Pulsipher, Michael A., Boyer, Michael W., August, Keith J., Myers, G. Doug, Tam, Constantine S., Jaeger, Ulrich, Foley, Stephen Ronan, Borchmann, Peter, Schuster, Stephen J., Waller, Edmund K., Awasthi, Rakesh, Potthoff, Bernd, Warren, Andy, Waldron, Edward R., McBlane, Fraser, Chassot-Agostinho, Andrea, Laetsch, Theodore W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153050/
https://www.ncbi.nlm.nih.gov/pubmed/34432863
http://dx.doi.org/10.1182/bloodadvances.2020003844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153050/
https://www.ncbi.nlm.nih.gov/pubmed/34432863
http://dx.doi.org/10.1182/bloodadvances.2020003844

Ejemplares similares